Cotización Recordati - REC

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Premium

Último Precio

48.50

Postura de Compra

47.62

Postura de Venta

48.84

Volume Operado de la Acción

318,373

47.70 Rango del Día 48.40

46.34 Rango de 52 semanas 60.50

Capitalización de Mercado [m]

9.96B

Precio Anterior

48.36

Precio de Apertura

48.20

Hora

48.5

Última hora de negociación

Volumen financiero

Precio Promedio Ponderado

Volumen promedio (3 m)

452,005

Acciones en circulación

205,358,104

Rendimiento del Dividendo

2.47%

Ratio Precio/Utilidad

25.85

Beneficio por acción (BPA)

1.9

turnover

2.07B

Beneficio neto

389.21M

Sector

Pharmaceutical Preparations

Industria

Pharmaceutical Preparations

Sitio web

www.recordati.it

Sede

Milan, Lombardy, Ita

Fundado

1926

Recordati SpA is listed in the Pharmaceutical Preparations sector of the Italian Stock Exchange with ticker REC. The last closing price for Recordati was 48.36 €. Over the last year, Recordati shares have traded in a share price range of 46.34 € to 60.50 €.

Recordati currently has 205,358,104 shares in issue. The market capitalisation of Recordati is 9.93 € billion. Recordati has a price to earnings ratio (PE ratio) of 25.85.

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S...

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED...

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5...

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE Milan, 4th October 2024 –...

Recordati Rare Diseases Announce Publication in the Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming the Efficacy and Safety of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease

The LINC 4 study demonstrated superiority of Isturisa® (osilodrostat) over placebo in achieving cortisol normalisation during the 12-week...

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICON...

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICONFERMANO...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	0.7	1.46443514644	47.8	48.4	47.12	317263	47.97775864	DE
4	-5.3	-9.85130111524	53.8	54.3	46.34	433747	51.008725	DE
12	-6.65	-12.0580235721	55.15	60.5	46.34	452005	54.30675023	DE
26	-4.6	-8.66290018832	53.1	60.5	46.34	351851	53.40586107	DE
52	-0.92	-1.86159449616	49.42	60.5	46.34	296380	52.09735438	DE
156	0.69	1.443212717	47.81	60.5	34.52	249741	46.74942133	DE
260	9.93	25.7453979777	38.57	60.5	34.52	274071	46.63580071	DE

REC - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Recordati?

El precio actual de las acciones de Recordati es 48.50 €

¿Cuántas acciones de Recordati están en circulación?

Recordati tiene 205,358,104 acciones en circulación

¿Cuál es la capitalización de mercado de Recordati?

La capitalización de mercado de Recordati es EUR 9.93B

¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Recordati?

Recordati ha negociado en un rango de 46.34 € a 60.50 € durante el último año

¿Cuál es el ratio PE (precio/beneficio) de Recordati?

El ratio precio/beneficio de Recordati es 25.85

¿Cuál es el ratio de efectivo a ventas de Recordati?

El ratio de efectivo a ventas de Recordati es 4.87

¿Cuál es la moneda de reporte de Recordati?

Recordati presenta sus resultados financieros en EUR

¿Cuál es el último ingresos anual de Recordati?

El último ingresos anual de Recordati es EUR 2.07B

¿Cuál es el último beneficio anual de Recordati?

El último beneficio anual de Recordati es EUR 389.21M

¿Cuál es la dirección registrada de Recordati?

La dirección registrada de Recordati es VIA MATTEO CIVITALI 1, MILAN, LOMBARDY, 20148

¿Cuál es la dirección del sitio web de Recordati?

La dirección del sitio web de Recordati es www.recordati.it

¿En qué sector industrial opera Recordati?

Recordati opera en el sector PHARMACEUTICAL PREPARATIONS

Símbolo	Precio	Vol.
BIABialetti Industrie Spa	0.45 € (61.29%)	6.72M
WHIK26Haiki Spa	0.0838 € (38.51%)	3.5k
WS3D25Solid World Group spa	0.045 € (34.73%)	26.25k
PREPredict SpA	0.89 € (20.27%)	330k
XHSXenia Hotellerie Solution SpA Societa Benefit	3.60 € (20.00%)	33.5k
WSOS26Sostravelcom SpA	0.0214 € (-47.55%)	13.6k
FDAFidia	0.0054 € (-18.18%)	18.73M
MTVFRMondo TV France	0.0045 € (-10.00%)	182k
TDTrenDevice Spa	0.11 € (-8.33%)	126k
1AMDAdvanced Micro Devices Inc	78.97 € (-7.09%)	15.51k
TITTelecom Italia SpA	0.3216 € (1.48%)	362.69M
ISPIntesa Sanpaolo Spa	4.3955 € (0.91%)	63.96M
SPMSaipem Spa	1.8195 € (1.03%)	37.76M
TITRTelecom Italia	0.3699 € (2.35%)	33.81M
STLAMStellantis NV	8.225 € (-1.13%)	28.35M

Símbolo

Precio

Vol.

TITTelecom Italia SpA

0.3216 €

(1.48%)

362.69M

ISPIntesa Sanpaolo Spa

4.3955 €

(0.91%)

63.96M

SPMSaipem Spa

1.8195 €

(1.03%)

37.76M

TITRTelecom Italia

0.3699 €

(2.35%)

33.81M

STLAMStellantis NV

8.225 €

(-1.13%)

28.35M

Datos

Noticias

Herramientas

Mercados

Descubrir

Hot Features

Follow Feed

Flujo de Opciones

Monitor

Recordati SpA (REC)

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Estadísticas y detalles clave

Acerca de Recordati SpA

REC Últimas noticias

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

Recordati Rare Diseases Announce Publication in the Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming the Efficacy and Safety of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICON...

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

REC - Preguntas Frecuentes

Movimientos

REC Finanzas

Discusión

Su Consulta Reciente

Empresa

Negocios

Popular

Obtener la aplicación

Tendencias Ahora

Listas Principales

Datos

Noticias

Herramientas

Mercados

Descubrir

Hot Features

Follow Feed

Flujo de Opciones

Monitor

Recordati SpA (REC) Cotización

Recordati SpA (REC)

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Estadísticas y detalles clave

Acerca de Recordati SpA

REC Últimas noticias

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

Recordati Rare Diseases Announce Publication in the Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming the Efficacy and Safety of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICON...

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

REC - Preguntas Frecuentes

Movimientos

REC Finanzas

Discusión

Su Consulta Reciente

Empresa

Negocios

Popular

Obtener la aplicación

Quitar anuncios